-- 新月能源公司（CRGY）週一公佈了第一季財報，數據顯示，其日均淨銷量為34.1萬桶油當量，高於去年同期的25.8萬桶油當量/日。 新月能源表示，其日均淨銷售量超出先前預期的32.8萬桶油當量/日約4%。 該公司報告稱，截至3月31日的第一季度，其石油日均淨銷售量為14萬桶，高於去年同期的10.2萬桶/日。 該公司表示，天然氣日均淨銷售量增加至7.43億立方英尺，高於去年同期的6.55億立方英尺/日。 該公司也表示，天然氣液體的日均淨銷售量為7.7萬桶，高於去年同期的4.7萬桶/日。 新月能源公司表示，迄今為止，在二疊紀盆地整合方面已實現約1.2億美元的成本節約，提前完成了原定目標。 該公司稱，第一季鑽探了38口自營井，其中37口井已投產；當季資本支出達3.85億美元。 新月能源公司於2026年第一季完成了兩項總額約3.55億美元的鷹灘頁岩油氣田礦產收購，進一步拓展了其未開發資源的投資組合。
Related Articles
Asia
Lottery Secures Agreement for 40-Year License Extension
Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.
$ASX:TLC
Asia
Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%
Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.
$ASX:GTK$NZE:GTK
Research
Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.
$VRTX